StreetInsider.com News Articles

Form SCHEDULE 13G InflaRx N.V. Filed by: Farallon Capital Partners, L.P.

Thu, 14 May 2026 08:28:00 -0400

si-local-file:///var/storage/secattach/20260514/26490555.html

Form SCHEDULE 13G InflaRx N.V. Filed by: Farallon Capital Partners, L.P.

Thu, 14 May 2026 08:28:00 -0400

si-local-file:///var/storage/secattach/20260514/26490555.html

Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy

Wed, 13 May 2026 07:16:01 -0400

(Updated - May 13, 2026 7:16 AM EDT)

Raymond James analyst Ryan Deschner upgraded Inflarx NV (NASDAQ: IFRX) from Outperform to Strong Buy with a price target of $9.00 (from $7.00).

The analyst comments "We are upgrading InflaRx (IFRX) to Strong Buy (price target to $9 from $7) following 1Q26 earnings, driven by our positive outlook on izicopan as a potentially very strong competitor in AAV. With the recent $150M raise in-hand, IFRX now has resource continuity to get izicopan through a proofof-concept study, where it could demonstrate a meaningfully differentiated liver toxicity profile vs. same-mechanism competitor, avacopan. Preclinical datasets suggest izicopan

Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy

Wed, 13 May 2026 07:16:01 -0400

(Updated - May 13, 2026 7:16 AM EDT)

Raymond James analyst Ryan Deschner upgraded Inflarx NV (NASDAQ: IFRX) from Outperform to Strong Buy with a price target of $9.00 (from $7.00).

Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy

Wed, 13 May 2026 07:16:01 -0400

(Updated - May 13, 2026 7:16 AM EDT)

Raymond James analyst Ryan Deschner upgraded Inflarx NV (NASDAQ: IFRX) from Outperform to Strong Buy with a price target of $9.00 (from $7.00).

Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy

Wed, 13 May 2026 07:16:01 -0400

(Updated - May 13, 2026 7:16 AM EDT)

Raymond James analyst Ryan Deschner upgraded Inflarx NV (NASDAQ: IFRX) from Outperform to Strong Buy with a price target of $9.00 (from $7.00).

Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy

Wed, 13 May 2026 07:16:01 -0400

(Updated - May 13, 2026 7:16 AM EDT)

Raymond James analyst Ryan Deschner upgraded Inflarx NV (NASDAQ: IFRX) from Outperform to Strong Buy with a price target of $9.00 (from $7.00).

Form SCHEDULE 13G InflaRx N.V. Filed by: TCG Crossover GP III, LLC

Tue, 12 May 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260512/26479668.html

Form SCHEDULE 13G InflaRx N.V. Filed by: TCG Crossover GP III, LLC

Tue, 12 May 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260512/26479668.html

InflaRx completes $150 million share offering at $2.00 per share

Fri, 08 May 2026 08:17:40 -0400

InflaRx N.V. (NASDAQ: IFRX) completed an underwritten offering of 75 million ordinary shares at $2.00 per share, generating $150 million in gross proceeds before underwriting discounts and expenses, according to a company statement.

The biopharmaceutical company, which develops anti-inflammatory therapeutics targeting the complement system, plans to use the net proceeds to advance pipeline activities and for working capital and general corporate purposes.

The offering attracted participation from both new and existing investors. New participants included TCGX, Farallon Capital Management, Sirenia Capital Management LP, Columbia Threadneedle Investments, Great Point Partners LLC, ADAR1 Capital Management, Coastlands Capital, Squadron Capital Management and other mutual funds.

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Fri, 08 May 2026 08:15:00 -0400

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.